Irinotecan Bendalis (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a pro‑drug that is converted inside cells to the active metabolite SN‑38. SN‑38 binds to the DNA‑topoisomerase I enzyme, preventing the religation of single‑strand DNA breaks during replication. This leads to accumulation of DNA damage, triggering apoptosis of rapidly dividing tumor cells.

The dose of Irinotecan Bendalis is individualized by the prescribing oncologist based on factors such as body surface area, disease stage, prior therapies, and organ function. No fixed regimen is provided here; clinicians determine the appropriate dosing schedule for each patient.

Safety data for Irinotecan Bendalis in pregnancy and lactation are limited. The drug is generally contraindicated during pregnancy unless the potential benefit justifies the risk, and breastfeeding is not recommended because the medication may be excreted in milk and harm the infant.

To place an order, submit an enquiry on the Irinotecan Bendalis product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class, differing from agents such as topotecan (another topoisomerase I inhibitor) and from DNA‑alkylating drugs like oxaliplatin. Its unique mechanism offers an alternative for patients who have progressed on other regimens, but it also carries a distinct toxicity profile, notably severe diarrhea and neutropenia.

Irinotecan Bendalis must be stored at 2‑8 °C in a refrigerator, protected from light and moisture. The product should not be frozen or shaken. Prior to administration, it should be inspected for particulate matter and prepared under aseptic conditions according to the manufacturer’s instructions.

Irinotecan Bendalis is administered intravenously, typically as an infusion over 30 to 90 minutes depending on the protocol. The infusion is performed by qualified healthcare professionals in a clinical setting, with appropriate monitoring for infusion‑related reactions and supportive care measures.

The most serious adverse events include febrile neutropenia, severe or life‑threatening diarrhea (colitis/ileitis), hepatic toxicity, and rare hypersensitivity reactions. Patients should be monitored closely for signs of infection, persistent gastrointestinal symptoms, and abnormal liver function tests, and managed promptly if they occur.

Irinotecan Bendalis should be avoided in patients with known hypersensitivity to irinotecan or any of its excipients, those with severe bone‑marrow suppression, uncontrolled infections, or significant hepatic impairment. Caution is also advised for individuals with known UGT1A1*28 homozygosity due to increased risk of toxicity.